Clinical and economic burden of pre‐emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients-Reference-Cited by-同舟云学术

Clinical and economic burden of pre‐emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients

Published:2019-09-03 Issue:1 Volume:92 Page:86-95
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

El Haddad Lynn¹,Ghantoji Shashank S.¹,Park Anne K.²,Batista Marjorie V.¹,Schelfhout Jonathan³,Hachem Jack¹,Lobo Yadira¹,Jiang Ying¹,Rondon Gabriela⁴,Champlin Richard⁴,Chemaly Roy F.¹^ORCID

Affiliation:

1. Department of Infectious Diseases, Infection Control and Employee HealthThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Office of Performance ImprovementThe University of Texas MD Anderson Cancer CenterHouston Texas

3. Merck & Co, IncKenilworth New Jersey

4. Department of Stem Cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHouston Texas

Funder

Merck

National Cancer Institute

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25574

Reference41 articles.

1. How we treat cytomegalovirus in hematopoietic cell transplant recipients

2. Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation

3. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

4. Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation

5. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2024-08

2. High infection rates and risk‐adapted prevention strategies in contemporary pediatric allogeneic hematopoietic stem cell transplantation;Pediatric Discovery;2024-07-14

3. Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation;Leukemia & Lymphoma;2024-03-12

4. [Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy];Farmeconomia. Health economics and therapeutic pathways;2023-12-07

5. Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective;Blood Advances;2023-12-06